Global Medical Morphine Market Size, Share Report, 2024 | Hexa Research

23 November 2018 -

The global Medical Morphine Market is expected to reach USD 13.32 billion by 2024, driven by increasing morphine consumption in the U.S. The increasing prevalence of arthritis and cancer in geriatric patients is projected to impact the morphine market globally positively.

North America dominated the market by contributing more than 75.0% of the share in 2016 and continue to dominate owing to the increasing number of prescriptions for morphine in the U.S. North American market for the same is expected to grow at a CAGR of 2.9% over the forecast period. However, lack of availability of medical morphine in countries such as India is expected to hamper the growth of the market.

In terms of route of administration, the oral segment is expected to grow at the fastest CAGR over the projected period owing to its dose accuracy, high accessibility, and ease of carrying compared to injectables and other counterparts.

On the basis of indication, others segment is expected to grow at the fastest CAGR of 3.1% over the forecast period owing to increasing number of prescriptions of morphine in U.S. for nominal conditions. The cancer segment is expected to exhibit lucrative growth due to increasing prevalence of bone cancer globally.

Browse Details of Report @ https://www.hexaresearch.com/research-report/medical-morphine-market

Morphine with its use in therapeutics is also one of the most abused drug globally. Respective governments are introducing initiatives to prevent substance abuse and decrease death rates caused by morphine.

Furthermore, researchers are concentrating on drug abuse treatment for opioid addicts which is expected to reduce the illicit use of morphine. For instance, in August 2017, researchers at University of California San Diego in collaboration with CARI therapeutics commenced development of a biosensor capable of detecting opioids in human bodies.

Hexa Research has segmented the global medical morphine market based on Route of Administration , Indication and region:

Segmentation by Route of Administration, 2014 - 2024 (USD Million)
• Oral
• Injectables
• Others

Segmentation by Indication, 2014 - 2024 (USD Million)
• Cancer
• Arthritis
• Others

Segmentation by Region, 2014 - 2024 (USD Million)
• North America
    • U.S.
• Europe
    • Germany
• Asia Pacific
    • China
    • India
• Rest of the World

Key players analyzed
• Mallinckrodt Pharmaceuticals
• Alcaliber S.A.
• Purdue Pharma L.P.
• Pfizer Inc.
• Johnson Matthey Fine Chemicals
• Sun Pharmaceutical Industries Ltd.
• Verve Health Care Ltd.
• Taj Pharmaceuticals Limited
• NORTHEAST PHARM
• MANUS AKTTEVA BIOPHARMA LLP

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

Global Oligonucleotide Testing Market Size, Analysis and Forecast to 2024

22 November 2018, The global Oligonucleotide Testing Market to reach USD 1,746.52 million by 2024, owing to the increasing research and development activities in the field of oligonucleotide. For instance, nowadays, multifunctional oligonucleotide based aptamer molecules are widely studied biomedical class among scientists across the globe. Due to its unique chemistry and potential advantages compared to currently available drugs (i.e. antibodies), aptamer became one of the most budding market for the future period.

With the rising concept of oligonucleotide as diagnostic, research and therapeutic agent, it is noticed that companies investigating the potential of oligonucleotide is going up. Number of small companies or start-ups entering the market is continuously increasing due to its potential advantages. Over the past few years, there has been explosive growth in number of research article published in the area of oligonucleotide and its products.

Browse Details of Report @ https://www.hexaresearch.com/research-report/oligonucleotide-testing-market

According to the open access journal Multidisciplinary Digital Publishing Institute (MDPI AG), in 1995, there were not more than 200 research articles on aptamers. Compare to this, now it is around 1800 research literatures published by scientist on aptamer assays or therapeutics. This number indicates that companies focusing on the oligonucleotide drugs is rising every year. This fact would in turn cause a surge in demand for oligonucleotide testing services, augmenting growth. However, strict regulatory framework is anticipated to hamper the market expansion to some extent.

Types segment is categorized into Instrument, Software, and Services. Among which, instrument segment captured the largest share of the total market. Introduction of technological advanced chromatographic columns coupled with increasing demand for oligonucleotide synthesis drive the segment growth. Instrument segment is further divided into liquid chromatography, mass chromatography and capillary electrophoresis. In terms of application, the market is segmented as research and commercial. Research segment capture the largest share owing to the strong product pipeline.

In 2016, North America dominated the market contributing a share of more than 40% in the revenue generated worldwide. The primary reason being the high growth of this region, particularly in the U.S. is the rising research and development activities on oligonucleotides. Asia pacific region was estimated to be the fastest growing region in the global market and is anticipated to grow at a CAGR of about 10.8% by 2024. The growing need for effective therapeutics, rising awareness level, coupled with the favorable government initiatives are expected to drive growth in this region.

Currently there are very less approved oligonucleotide drugs namely fomivirsen (Vitravene), pegaptanib (Macugen), and mipomersen (Kynamro). Of which mipomersen and fomivirsen acti through RNase H mediated cleavage of targeted RNA. These drugs were developed by Ionis Pharmaceuticals. As the number of drugs available in the market are less, the oligonucleotide pipeline is strong and is expected to show positive response over the projection period.

Technological advances in development of oligonucleotide products has been one of the major market driver. Oligonucleotide synthesis has undergone tremendous changes which has resulted in rapid synthesis and cost-effective techniques of oligomer synthesis. Improvement of synthesis methods which include high throughput synthesizers, better coupling reagents and new sets of protective amino groups has drastically changed the nucleotide synthesis chemistry. With rapid development in oligonucleotide synthesis, the testing market is also expected to show lucrative growth. The major players are focusing on quality, service and innovation and adopting strategies such as product portfolio expansion, capacity expansions, and development of new facilities to gain market share.

Hexa Research has segmented the global personal protective equipment market report based on product type, application and region:

Segmentation by Type, 2014 - 2024
    • Instrument
        • Liquid Chromatography
        • Mass Chromatography
        • Capillary Electrophoresis
    • Software
    • Service

Segmentation by application, 2014 - 2024
    • Research
    • Commercial

Segmentation by region, 2014 - 2024
    • North America
        • U.S.
    • Europe
        • Germany
        • UK
    • Asia Pacific
        • China
        • India
    • Rest of the world (RoW)

Key players analyzed:
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Integrated DNA Technologies, Inc.
    • Agilent Technologies
    • Bruker

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

U.S. Wound Dressing Market Research Report - Analysis and Forecast to 2024

13 November 2018 -

The US Wound Dressing Market size is expected to reach USD 4.25 billion by 2024. Growing aging population and cases of diabetes and obesity are the major factors driving the market. Furthermore, increasing incidence of pressure ulcers in bedridden, wheelchair-bound, and/or physically impaired patients is expected to fuel the demand for wound care over the forecast period. For instance, annually, 2.5 million individuals suffer from pressure ulcer in U.S. and around USD 9.1 billion to USD 11.6 billion are spent for its treatment.

Moreover, growing cases of surgical procedures due to high incidence of wound infections and diabetic foot are expected to boost the demand for wound dressing. This has also increased the preference for advanced wound care products over simple dressing. Advanced dressing offers rapid healing, reasonable cost, with minimal inconvenience to the patient. However, owing to the demand for low cost dressing, traditional methods are being used to some extent. This may have a negative impact on the market development over the forecast period.

However, availability of various insurance schemes in U.S. for affordable medical care over long term, coupled with rise in consumer disposable income, is encouraging people to opt for advanced healthcare. This is anticipated to contribute to market expansion over the years to come.

Browse Details of Report @ https://www.hexaresearch.com/research-report/us-wound-dressing-market

The advanced dressing technique is the fastest-growing segment expanding at a CAGR of 4.4% over the forecast period. It also held the dominant market share of USD 1.8 billion in 2017. It is expected to reach USD 2.6 billion by 2024. Advanced dressings includes moist, antimicrobial, and active dressings. Factors such as rapid healing and minimal patient inconvenience are anticipated impel this growth over the forecast period.

Chronic and non-healing wounds are best treated with advanced wound dressing products. Limitations of traditional wound care have propelled the growth of the segment. Advanced moist wound care is recommended for chronic wounds like pressure and diabetic ulcers, burn injuries, and other slow-healing wounds. Advanced foam technique is essential to prevent and heal the exudation of burn injuries. All these factors are projected to propel the growth of the U.S. wound dressing market during the forecast period.

Advanced alginate dressing is recommended in highly exuding wounds, as it forms a gel around the wound bed and helps in keeping them dry and clean. Advanced alginate dressing have gel-forming ability and they also help reduce the pain. As a result, they are widely used for the treatment for bleeding wounds. Advanced films provide healing to semi-dry and dry wounds. Advanced hydrocolloid dressing helps protect the wound internally, as well as externally. Increasing number of surgeries is expected to fuel the growth of hydrogel dressings. All these factors are expected to propel the growth of the wound dressing market over the forecast period.

Antimicrobial dressings are easy to use, accessible without prescription, and less risk of resistant. Silver and non-silver are the two types of this dressings. Silver shows broad spectrum antibacterial activity and minimal toxicity towards host cells. The non-sliver wound dressing may have single or combination of various ingredients, such as iodine, chlorhexidine, Polyhexamethylbuguanide (PHMB), honey, acetic acid, and potassium permanganate. This type of dressing is used for faster healing process and for reducing the pain. Active wound dressings are administered for the repair and healing through bioactive and skin-substitute compounds. They are highly beneficial in healing chronic moist wounds.

Hexa Research has segmented the U.S. wound dressing market report based on product:-

Segmentation by Product Type, 2013 - 2024
    • Traditional
    • Advanced
        • Moist
            • Foam
            • Alginate
            • Films
            • Hydrocolloids
            • Hydrogel
        • Antimicrobial
            • Silver
            • Non-silver
        • Active
            • Biomaterials
            • Skin-substitute

Key Players Analyzed:
    • 3M Healthcare
    • Coloplast
    • Medline Industries
    • HARTMANN.
    • BSN Medical
    • Medtronic Plc
    • Smith & Nephew
    • ConvaTec
    • Derma Sciences
    • Systagenix

 Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry